FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Lippa Arnold						2. Issuer Name and Ticker or Trading Symbol CORTEX PHARMACEUTICALS								(Check a	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
							INC/DE/[CORX]								Director			10% O	-	
(Last)	(First	,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year)									Officer (gi		below		specify	
C/O CORTEX PHARMACEUTICALS, INC.						0.000,2010									Chairman, CEO & President					
126 VALLEY ROAD, SUITE C							4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)														X	Form filed	by One	Repo	rting Pers	on	
GLEN ROC	K NJ		07452												Form filed by More than One Reporting Person				orting	
(City)	(Stat	te)	(Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day						Execution Date		Date,	3. Transaction Code (Instr.		4. Securities Acquired Disposed Of (D) (Instr. and 5)			tr. 3, 4	5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										v	Amount (A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)						
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
Security (Instr. 3) or E Pric Deri	Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title a	and Amou	int of	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned		10. Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
	Security				Code	V (A) ((D)	Date Exercisable	Expiration Date		Title	- 1	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)		(I) (Instr. 4)		
Common Stock Options (to purchase shares of Common Stock)	\$0.025	06/30/2015		А			15,000,000		(1)	06/30/2022		Common Stock 15,		15,000,000	\$0	15,000	0,000	D		

Explanation of Responses:

1. These Common Stock Options vest in three installments: 50 percent on June 30, 2015, 25 percent on September 30, 2015, and 25 percent on December 31, 2015.

<u>/s/ Arnold S. Lippa</u> <u>07/02/2015</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.